Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic Oncology

Video

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

In an interview with CancerNetwork®,Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, discussed encouraging research in the field of urologic oncology.

Transcription:

From a new treatment standpoint, some of [the most interesting] areas in prostate, kidney, and bladder cancer [are] the continued immunotherapy developments. Another one that’s very relevant to our world today is continued disparities research. [With] disparities, everyone always initially tends to think of gender and racial disparities; I think inherent into that [are] also very significant socioeconomic and also geographic disparities.

I think there’s going to be new ways of providing urologic care and telemedicine will be one tool for that. I do not think that…telemedicine will fix all disparity access issues for urologic care. I think that that is an over promise for this technology. But I think it can help and it can be used as a tool [for] the person who lives 500 miles away from a referral center [who has] a unique cancer that probably should…at least have treatment guided by that referral center. [This technology] makes it just a lot easier for them to get the input because they don’t have to drive 500 miles or fly that far. They can just have a telemedicine visit from their couch and say, ‘Okay, my local provider can do this, this is great. Thank you so much for your guidance and input,’ and [get] on with their day.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content